Relationship between chronic kidney disease and metabolic syndrome: Current perspectives

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 421-435

  Nashar, Khaled ^a   Egan, Brent M ^b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

Adipokines; Hypertension; Inflammation; Insulin resistance; Obesity; Oxdative stress

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OLMESARTAN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; GLOMERULOPATHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; METABOLIC SYNDROME X; MICROALBUMINURIA; NONHUMAN; OBESITY; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; WEIGHT REDUCTION;

EID: 84907876963     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S45183     Document Type: Review

References (115)

1. Kylin E. Studies of the hypertension-hyperglycemia-hyperuricemia syndrome. Zentralbl Inn Med. 1923;44:105–127. German.
2. Herman JB, Medalie JH, Goldbourt U. Diabetes, prediabetes and uricae­mia. Diabetologia. 1976;12(1):47–52.
3. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
5. Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91(6):1169–1184.
6. Caterson ID, Hubbard V, Bray GA, et al; American Heart Association. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity. Circulation. 2004;110(18):e476–e483.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359.
8. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin. 2010;26(3):713–719.
9. Kidney Disease: Improving Gobal Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evalua­tion and management of chronic kidney disease. Kidney Int Supp. 2013;3(1):1–150.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
11. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7): 2034–2047.
12. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132.
13. Li W, Ma D, Liu M, et al. Association between metabolic syndrome and risk of stroke: a meta-analysis of cohort studies. Cerebrovasc Dis. 2008;25(6):539–547.
14. Wu SH, Hui WS, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25(6):375–384.
15. Agrawal S, Shlipak MG, Kramer H, Jain A, Herrington DM. The association of chronic kidney disease and metabolic syndrome with incident cardiovascular events: multiethnic study of atherosclerosis. Cardiol Res Pract. 2012;2012:806102.
16. Kunimura A, Amano T, Uetani T, et al. Prognostic impact of concurrence of metabolic syndrome and chronic kidney disease in patients undergoing coronary intervention: involvement of coronary plaque composition. J Cardiol. 2013;61(3):189–195.
17. Kim CS, Choi JS, Bae EH, et al; Korea Acute Myocardial Infarction Registry Investigators. Association of metabolic syndrome and renal insufficiency with clinical outcome in acute myocardial infarction. Metabolism. 2013;62(5):669–676.
18. Chan DT, Watts GF, Irish AB, Ooi EM, Dogra GK. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease. Am J Hypertens. 2013;26(9):1155–1161.
19. Xu H, Huang X, Arnlöv J, et al. Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. Clin J Am Soc Nephrol. 2014;9(4):690–697.
20. Johnson DW, Armstrong K, Campbell SB, et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic sig­nificance and effects of risk factor modification. Nephrology (Carlton). 2007;12(4):391–398.
21. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140(3): 167–174.
22. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16(11 Pt 1):952–958.
23. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134–2140.
24. Cuspidi C, Meani S, Fusi V, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004;22(10):1991–1998.
25. Mulè G, Nardi E, Cottone S, et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med. 2005;257(6): 503–513.
26. Chen J, Gu D, Chen CS, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22(4):1100–1106.
27. Lucove J, Vupputuri S, Heiss G, North K, Russell M. Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study. Am J Kidney Dis. 2008;51(1):21–28.
28. Sun F, Tao Q, Zhan S. Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort. Nephrology (Carlton). 2010;15(1):84–92.
29. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69(2):369–374.
30. Chang IH, Han JH, Myung SC, et al. Association between metabolic syndrome and chronic kidney disease in the Korean population. Nephrology (Carlton). 2009;14(3):321–326.
31. Surendar J, Indulekha K, Aravindhan V, Ganesan A, Mohan V. Association of cystatin-C with metabolic syndrome in normal glucose-tolerant subjects (CURES-97). Diabetes Technol Ther. 2010;12(11): 907–912.
32. Yang T, Chu CH, Hsu CH, et al. Impact of metabolic syndrome on the incidence of chronic kidney disease: a Chinese cohort study. Nephrology (Carlton). 2012;17(6):532–538.
33. Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48(3):383–391.
34. Ryu S, Chang Y, Woo HY, et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis. 2009;53(1):59–69.
35. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navanee­than SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10): 2364–2373.
36. Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol. 2007;2(5):976–983.
37. Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009;53(5):751–759.
38. Kohler KA, McClellan WM, Ziemer DC, Kleinbaum DG, Boring JR. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis. 2000;36(5):903–913.
39. Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol. 2002;13(6):1626–1634.
40. Niskanen LK, Penttilã I, Parviainen M, Uusitupa MI. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care. 1996;19(5):486–493.
41. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14(2):469–477.
42. Nerpin E, Risérus U, Ingelsson E, et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care. 2008;31(8): 1550–1555.
43. Li Y, Xie D, Qin X, et al. Metabolic syndrome, but not insulin resistance, is associated with an increased risk of renal function decline. Clin Nutr. Epub April 16, 2014.
44. Aksentijević D, Bhandari S, Seymour AM. Insulin resistance and altered glucose transporter 4 expression in experimental uremia. Kidney Int. 2009;75(7):711–718.
45. Sun DF, Chen Y, Rabkin R. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int. 2006;70(3):453–459.
46. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis. 1992;19(6):505–513.
47. Feneberg R, Sparber M, Veldhuis JD, Mehls O, Ritz E, Schaefer F. Altered temporal organization of plasma insulin oscillations in chronic renal failure. J Clin Endocrinol Metab. 2002;87(5):1965–1973.
48. Hager SR. Insulin resistance of uremia. Am J Kidney Dis. 1989; 14(4):272-276.
49. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67(2):563–568.
50. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53(5):1343–1347.
51. Kato Y, Hayashi M, Ohno Y, Suzawa T, Sasaki T, Saruta T. Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis. Clin Nephrol. 2000;54(5):366–373.
52. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45(2):275–280.
53. Landau M, Kurella-Tamura M, Shlipak MG, et al; Health, Aging and Body Composition Study. Correlates of insulin resistance in older individuals with and without kidney disease. Nephrol Dial Transplant. 2011;26(9):2814–2819.
54. Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY, Wu KD. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal func­tion in elderly. J Clin Endocrinol Metab. 2012;97(4):1268–1276.
55. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemo­dialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000;15(1):65–70.
56. Kovács T, Vas T, Kovesdy C, et al. Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy. Clin Kidney J. 2012;0:1–7.
57. Saito T, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Metabolic syn­drome and risk of progression of chronic kidney disease: a single-center cohort study in Japan. Heart Vessels. 2013;28(3):323–329.
58. Wang C, Blough ER, Arvapalli R, et al. Metabolic syndrome-induced tubulointerstitial injury: role of oxidative stress and pre­ventive effects of acetaminophen. Free Radic Biol Med. 2013;65:1417–1426.
59. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15(11):2792–2800.
60. Lee JE, Choi SY, Huh W, Kim YG, Kim DJ, Oh HY. Metabolic syndrome, C-reactive protein, and chronic kidney disease in non­diabetic, nonhypertensive adults. Am J Hypertens. 2007;20(11):1189–1194.
61. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21(6): 697–738.
62. Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am. 2009;93(3):569–582.
63. Nashar K, Nguyen JP, Jesri A, Morrow JD, Egan BM. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. Am J Hypertens. 2004;17(6):477–482.
64. Taal MW. Arterial stiffness in chronic kidney disease: an update. Curr Opin Nephrol Hypertens. 2014;23(2):169–173.
65. Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular cisease. Cardiol Res Pract. 2011;2011:963517.
66. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39(1):1–11.
67. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr. 1989;67(17):858–864.
68. Kon V. Neural control of renal circulation. Miner Electrolyte Metab. 1989;15(1–2):33–43.
69. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [see comments]. Kidney Int. 1999;56(3):860–872.
70. Kim HJ, Vaziri ND, Norris K, An WS, Quiroz Y, Rodriguez-Iturbe B. High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease. Clin Exp Nephrol. 2010;14(6):536–547.
71. Praga M. Obesity – a neglected culprit in renal disease. Nephrol Dial Transplant. 2002;17(7):1157–1159.
72. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–312.
73. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adi­pocytes and vascular function. J Clin Endocrinol Metab. 2004;89(6): 2563–2568.
74. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118(5): 1645–1656.
75. Becker B, Kronenberg F, Kielstein JT, et al; MMKD Study Group. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16(4):1091–1098.
76. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(1):134–141.
77. Preble WE. Obesity: observations on one thousand cases. Boston Med Surg J. 1923;188:617–621.
78. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–28.
79. Chen S, Chen Y, Liu X, et al. Association of insulin resistance with chronic kidney disease in non-diabetic subjects with normal weight. PLoS One. 2013;8(9):74058.
80. Ryu S, Chang Y, Woo HY, et al. Changes in body weight predict CKD in healthy men. J Am Soc Nephrol. 2008;19(9):1798–1805.
81. Praga M, Hernández E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000;58(5):2111–2118.
82. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498–1509.
83. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract. 2009;113(1):c16–c23.
84. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19–33.
85. Munkhaugen J, Lydersen S, Widerøe TE, Hallan S. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis. 2009;54(4):638–646.
86. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366(9491):1059–1062.
87. Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab. 2002;87(11):5044–5051.
88. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52(10):2490–2496.
89. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96(1):88–98.
90. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997;46(10): 1579–1585.
91. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13–18.
92. Jiang X, Srinivasan SR, Radhakrishnamurthy B, Dalferes ER. Jr, Bao W, Berenson GS. Microalbuminuria in young adults related to blood pressure in a biracial (black-white) population. The Bogalusa Heart Study. Am J Hypertens. 1994;7(9 Pt 1):794–800.
93. Srinivasan SR, Myers L, Berenson GS. Risk variables of insulin resistance syndrome in African-American and Caucasian young adults with microalbuminuria: the Bogalusa Heart Study. Am J Hypertens. 2000;13(12):1274–1279.
94. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26(4):670–675.
95. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293–301.
96. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(16):1908–1919.
97. Bose S, Bomback AS, Mehta NN, et al; KEEP investigators. Dysglycemia but not lipids is associated with abnormal urinary albu­min excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). BMC Nephrol. 2012;13:104.
98. Agrawal V, Shah A, Rice C, Franklin BA, McCullough PA. Impact of treating the metabolic syndrome on chronic kidney disease. Nat Rev Nephrol. 2009;5(9):520–528.
99. Bestermann W, Houston MC, Basile J, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovas­cular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci. 2005;329(6):292–305.
100. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifac­torial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353(9153):617–622.
101. Hallan S, de Mutsert R, Carlsen S, Dekker FW, Aasarød K, Holmen J. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis. 2006;47(3):396–405.
102. Finkelstein J, Joshi A, Hise MK. Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2006;48(3):372–382.
103. Ibrahim HN, Weber ML. Weight loss: a neglected intervention in the management of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(6):534–538.
104. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278(5):F817–F822.
105. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793–808.
106. Lindholm A, Bixo M, Björn I, et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2008;89(5):1221–1228.
107. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin. 2005;21(12):1997–2006.
108. Kurata A, Nishizawa H, Kihara S, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006;70(10): 1717–1724.
109. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260–269.
110. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182.
111. Kitiyakara C, Yamwong S, Cheepudomwit S, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int. 2007;71(7):693–700.
112. Bakker SJ, Gansevoort RT, de Zeeuw D. Metabolic syndrome: a fata morgana? Nephrol Dial Transplant. 2007;22(1):15–20.
113. Lea JP, Greene EL, Nicholas SB, Agodoa L, Norris KC. Cardiorenal metabolic syndrome in the African diaspora: rationale for including chronic kidney disease in the metabolic syndrome definition. Ethn Dis. 2009;19(2 Suppl 2):S2–S11.
114. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol. 2013;164(2): 141–150.
115. Lea J, Cheek D, Thornley-Brown D, et al; AASK Study Investigators. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis. 2008;51(5): 732–740.